Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Sonazoid × 1 year × Clear all
NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

The Netherlands Cancer Institute

Phase 2/3 Recruiting
91 enrolled
BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡